trial

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness

NCTId NCT03935854
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 23 (actual)
Sponsored by Stanford University
Primary completion 2022-08-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
23 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-02-13
Primary completion
2022-08-11
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
LCHF, Ketogenic Diet

Sponsors

Stanford UniversityLead Sponsor

Investigators

1
Shebani Sethi, MDPrincipal Investigator

Sites

1 total
Stanford, United States

Facts & assertions

4 sourced
Enrollment
23
Phase
NA
Primary Completion Date
2022-08-11
Status
COMPLETED
relationships
The graph out of here
drug
LCHF, Ketogenic Diet
drug
lead_sponsor
Stanford University
company
indication
Psychotropic Agents Causing Adverse Effects in Therapeutic Use
indication
Bipolar Disorder
indication
Weight Gain
indication
investigator
Shebani Sethi, MD
person